DIKUL - logo
(UL)
  • Semaglutid - prvi peroralni agonist receptorjev GLP-1 za zdravljenje sladkorne bolezni tipa 2 = Semaglutide - the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes
    Jovanović, Marija, farmacevtka ...
    Optimal glycemic control and multifactorial treatment are important for type 2 diabetes control. Non-pharmacological treatment is the mainstay of antihyperglycemic treatment, but it usually merits ... timely escalation of pharmacological intervention. One of the barriers to pharmacological treatment with GLP-1 receptor agonists was injectable treatment due to their polypeptide composition. In 2019, the first and only oral GLP-1 receptor agonist – semaglutide, was introduced to clinical use. Due to structural modifications and technological processing of the tablet, the molecule is resistant to degradation in the acidic gastric envi- ronment and has a comparable effect as in the form of injectable treatment. Oral semaglutide was effective in improving glycemic control and redu- cing body weight, and proven for its cardiovascular safety. The present article describes the mechanism of action of GLP-1 receptor agonists, the development of oral semaglutide, dosing instructions and data from studies of its efficacy and safety.
    Source: Farmacevtski vestnik : strokovno glasilo slovenske farmacije = pharmaceutical journal of Slovenia. - ISSN 0014-8229 (Letn. 73, št. 3, jul. 2022, str. 231-240)
    Type of material - article, component part ; adult, serious
    Publish date - 2022
    Language - slovenian
    COBISS.SI-ID - 114653443

    Link(s):

    https://www.sfd.si/wp-content/uploads/2022/06/fv-3-2022-net.pdf
    Digitalna knjižnica Slovenije - dLib.si

Shelf entry